The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) who purchased shares between September 6, 2017 and August 19, 2019. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the Sarepta lawsuit alleges that (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
Shareholders have until October 29, 2019 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >